134 Chapter 5 5 Acknowledgement We thank the members of the patient advisory panel (J Donkers, B Frankemölle, J Groenendijk and S Sturkenboom) for their valuable input in the set up and execution of this study. We thank Nan van Geloven for statistical advice. AstraZeneca was provided the opportunity to review the manuscript; full editorial control remained with the authors. Authors’ contributions SJvdH and CCP contributed equally to this paper. SJvdH, CCP, EM, JFMvB, MJP, LNvdB, BMJF-dB, NHC and JWHK made substantial contributions in the conception and design of the study. SJvdH and CCP wrote the first version and subsequent versions of this manuscript. All authors reviewed the article critically for important intellectual content and gave final approval of the version to be published. Funding This study is funded by AstraZeneca following a research collaboration agreement. This funding body made suggestions for design of this study but final decisions regarding the design were made by the authors. The funding body is not involved in data collection and study management, and will not be involved in the analysis and interpretation of data. Reports will be reviewed for IP rights by the funding body, but the funding body has no influence on the decision to submit reports for publication. Competing interests statement JWHK reports grants, personal fees and non-financial support outside the submitted work from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim and GSK; grants and personal fees from Chiesi Pharmaceuticals and TEVA; grants from Mundi Pharma and personal fees from MSD and COVIS Pharma; JWHK also holds 72.5% of shares in the General Practitioners Research Institute. JFMVB received grants and/or consultancy fees from AstraZeneca, Chiesi, European Commission COST (COST Action 19132), GSK, Novartis, Teva and Trudell Medical, outside the submitted work and all paid to his institution. BFdB was employed by General Practitioners Research Institute (GPRI) at the time of the study. In the past three years (2019-2021), GPRI conducted investigator-initiated and sponsorinitiated research funded by non-commercial organisations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva). Patient and public involvement Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details. Patient consent for publication Not applicable.
RkJQdWJsaXNoZXIy MTk4NDMw